Eli Lilly will soon bring a pill version to the market, with a version expected to debut at a lower price than injectable Ozempic or Wegovy did. A generic GLP-1 agonist is on track to arrive at ...

Could this be an excellent opportunity for investors to scoop up shares of these companies on the dip? That's the case if ...

The US Food and Drug Administration (FDA) granted approval for a second treatment for metabolic dysfunction-associated ...